Distribution · Latin America · Announced 29 Sept 2026

Kyowa Kirin → Knight Therapeutics

Kyowa Kirin International has granted Knight Therapeutics exclusive rights to seek approval for and distribute the CCR4 antibody Poteligeo (mogamulizumab) for cutaneous T-cell lymphoma in Brazil, Mexico, Colombia and Argentina; terms undisclosed.

Parties: Kyowa Kirin International (United Kingdom) → Knight Therapeutics (Canada)

Deal type
Distribution
Value
Undisclosed
Territory
Brazil, Mexico, Colombia and Argentina
Therapeutic area
Oncology
Assets
Poteligeo; mogamulizumab
Announced
29 Sept 2026

Our analysis

Why this matters

On 29 September 2026, Knight Therapeutics (Montreal, TSX: GUD) signed an exclusive distribution agreement with Kyowa Kirin International (KKI), a wholly owned subsidiary of Japan's Kyowa Kirin Co., Ltd., for Poteligeo (mogamulizumab) in Brazil, Mexico, Colombia and Argentina. Knight is responsible for obtaining regulatory approval and commercialising the product in all four countries. Financial terms and duration were not disclosed.

Poteligeo is a humanised monoclonal antibody targeting CCR4. In the US and Europe it is approved for adults with relapsed or refractory mycosis fungoides or Sézary syndrome, the two main forms of cutaneous T-cell lymphoma (CTCL), after at least one prior systemic therapy. Trade press describe the deal as Kyowa Kirin's first commercial partnership for mogamulizumab in Latin America.

The full analysis is free to read with a work email on this page.

Source: Knight Therapeutics press release (GlobeNewswire); Pharmaceutical Technology

Latest deals

All Latin America deals → · All distribution deals → · Browse all emerging-market pharma deals →